Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy

Developing new therapeutic agents for cancer immunotherapy is highly demanding due to the low response ratio of PD-1/PD-L1 blockade in cancer patients. Here, we discovered that the novel immune checkpoint VISTA is highly expressed on a variety of tumor-infiltrating immune cells, especially myeloid d...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Xiaoshuang, Wu, Menghan, Li, Guodong, Zhou, Xiuman, Cao, Wenpeng, Zhai, Wenjie, Wu, Aijun, Zhou, Xiaowen, Jin, Shengzhe, Chen, Guanyu, Li, Yanying, Du, Jiangfeng, Wu, Yahong, Qiu, Lu, Zhao, Wenshan, Gao, Yanfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638518/
https://www.ncbi.nlm.nih.gov/pubmed/37969728
http://dx.doi.org/10.1016/j.apsb.2023.08.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638518/
https://www.ncbi.nlm.nih.gov/pubmed/37969728
http://dx.doi.org/10.1016/j.apsb.2023.08.003

Ejemplares similares